Mathematical justification of advantage of Hodgkin's lymphoma risk-adapted therapy in children and adolescents

Abstract

The aim of the study was confirmation of advantage risk-adapted therapy by creation of mathematical models of the individual forecast of Hodgkin’s lymphoma in children and adolescents. Material and methods. Data of 138 patients with Hodgkin’s lymphoma aged from 4 to 18 years old (median 14 years old) treated on risk-adapted programs are included in the investigation. Results. Two factors significant increased recurrence risk at criteria selection and assessment: disease IV stage (correlation coefficient of 0,1904, p=0,024) and B symptoms (correlation coefficient of 0,1876, p=0,026). It wasn’t revealed collinear signs. The regression equation looked as follows: y =-0,156702+0,056748Х st + 0,092922Х В; the determination coefficient was 0,05241494. Separate elements and the whole equation stopped being significant in multiple regression analysis that doesn’t allow to use them for forecasting of lymphoma recurrence. Conclusion. Thus, inclusion in the correlation analysis of the parameter «treatment program» levels influence of adverse factors on the recurrence, and proves adequacy of selection of therapy burden and advantage of risk-adapted protocols before the unified programs. It is once again proved that it is necessary to consider the principles of «response-adapted therapy» when effective treatment partially compensate negative influence of some adverse signs, minimizing their weight in prognostic models.

Keywords

children / Hodgkin’s lymphoma / risk-adapted therapy / prognostic factors / adolescents

References

[1] Carde P., Koscielny S., Franklin J., Axdorph U., Raemaekers J., Diehl V. et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkin’s disease patients that should influence initial treatment length and intensity? Ann. Oncol. 2002; 13(1): 86-91.

[2] Foltz L.M., Song K.W., Connors J.M. Hodgkin’s lymphoma in adolescents. J. Clin. Oncol. 2006; 24(16): 2520-6.

[3] Schellong G., Bramswig J.H., Hornig-Franz I., Schwarze E.W., Potter R., Wannenmacher M. Hodgkin’s disease in children: combined modality treatment for stages IA, IB and IIA. Ann. Oncol. 1994; 5(2): 113-5.

[4] Schellong G., Potter R., Bramswig J., Wagner W., Prott F.J., Dorffel W. et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin’s disease: the German-Austrian Multicenter Trial DAL-HD-90. J. Clin. Oncol. 1999; 17(12): 3736-44.

[5] Кулева С.А., Анишкин М.Ю., Колыгин Б.А. Лимфома Ходжкина у детей и подростков: эффективность риск-адаптированного протокола СПбЛХ-05. Детская онкология. 2007; 3-4: 16-21.

[6] Kulyova S.A., Kolygin B.A. Hodgkin’s lymphoma in children and adolescents: a Saint Petersburg Hodgkin’s Lymphoma Group Study. J. Oncol. 2011. Available at: http://dx.doi.org/10.1155/2011/958435.

[7] Gobbi P.G., Comelli M., Grignani G.E., Pieresca C., Bertoloni D. , Ascari E. et al. Estimate of expected survival at diagnosis in Hodgkin’s disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin’s Disease (IDHD). Haematologica. 1994; 79: 241-55.

[8] Hasenclever D., Diehl V. A prognostic score to predict tumor control in advanced Hodgkin’s disease. N. Engl. J. Med. 1998; 339: 1506-14.

[9] Klimm B., Goergen H., Fuchs M., von Tresckow B., Boll B., Meissner J. et al. Impact of risk factors on outcomes in early-stage Hodgkin’s lymphoma: an analysis of international staging definitions. Ann. Oncol. 2013; 24(12): 3070-6.

[10] Юнкеров В.И., Григорьев С.Г., Резванцев М.В. Математико-статистическая обработка данных медицинских исследований. СПб.: ВМедА; 2011.

RIGHTS & PERMISSIONS

Eco-Vector